Asymptomatic, Enlarging Plaque: Your Dx?

News
Poll

This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals. Which of the following statements is true?

This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals.

Which of the following statements is true?

A. The absence of epidermal scaling argues against tinea corporis.
B. Lesion location and appearance strongly suggest granuloma annulare.
C. The patient's age also suggests granuloma annulare.
D. Dyslipidemia is positively associated with granuloma annulare.
E. Granuloma annulare is often self-limited, but topical steroids may hasten resolution.
F. All of the above are true.
Related Content
Mental Health Burden in Atopic Dermatitis: Study Identifies Key Risk Factors for Anxiety and Depression / image credit ©martialred/stock.adobe.com

Mental Health Burden in Atopic Dermatitis: Study Identifies Key Risk Factors for Anxiety and Depression

Grace Halsey
July 2nd 2025
Article

Depression and anxiety affect as many as 1 in 4 people with AD, with pruritis, sleep disorders, education level, and comorbidities identified as independent risk factors.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Investigational Respegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational Rezpegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis

Grace Halsey
June 25th 2025
Article

In the phase 2b trial, the IL-2 pathway agonist and Treg proliferator demonstrated a strong dose-dependent biological response across 3 treatment arms vs placebo.

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid in Adults

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid in Adults

Sydney Jennings
June 20th 2025
Article

Dupilumab is the first targeted treatment for B to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.

/ image credit ©Billion Photos/stock.adobe.com

Teledermatology-Dermoscopy Program Could Help Reduce Inequities in Skin Cancer Screening

Grace Halsey
June 20th 2025
Article

A student-led teledermatology-dermoscopy initiative that identified skin lesions in underserved communities could be a scalable model for early skin cancer detection and care.

Key Updates in Atopic Dermatitis for Primary Care

Key Updates in Atopic Dermatitis for Primary Care

Sydney Jennings
June 13th 2025
Article

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

© 2025 MJH Life Sciences

All rights reserved.